Type: rating_growth

Analysts Citi, Deutsche Bank, UBS, Bank of America, and Barclays raise price targets for Marvell Technology (MRVL) following strong earnings report

05/28/2026, 11:34 AM investing rating_growth Analysts semiconductors

Marvell Technology's recent quarterly earnings exceeded expectations, prompting several analysts to raise their price targets and maintain buy ratings, indicating strong future growth potential despite a slight premarket stock decline.

Bread Financial Raises 1-Year CD Yield to 4% Amidst Economic Uncertainty

05/27/2026, 07:32 PM investing rating_growth Analysts: BTIG finance

Despite a challenging outlook for Federal Reserve rate cuts this year, some banks are offering competitive yields on cash instruments, providing opportunities for savers amid rising inflation and fuel prices.

Analysts UBS tripled Micron Technology (MU) price target to $1,625 amid AI demand surge

05/27/2026, 04:32 PM investing rating_growth Analysts: analysts, UBS ai semiconductors

Micron Technology's inclusion in Goldman Sachs' 'Hedge Fund VIP' basket highlights strong hedge fund interest, coinciding with a significant surge in its stock price driven by AI demand for memory chips.

Analysts JPMorgan upgrade Openlane (OPLN) to overweight and raise target price to $38, citing strong growth potential

05/27/2026, 12:32 PM investing rating_growth Analysts: analysts, JPMorgan

Recent analyst upgrades and downgrades reflect shifting market sentiments, with notable upgrades for Openlane and MGM, while Dollar General faces challenges, indicating potential investment opportunities and risks for investors.

Analysts JPMorgan upgraded FedEx (FDX) to overweight and raised target price to $460, anticipating 15% upside post freight business spinoff

05/27/2026, 12:32 PM investing rating_growth Analysts: analysts, JPMorgan transportation

JPMorgan has upgraded FedEx to overweight and raised its price target, citing the upcoming spin-off of its freight business as a catalyst for improved operational momentum and financial visibility.

Analysts Barclays upgraded Sandisk (SNDK) to overweight and raised target price to $2,300, expecting 45% upside

05/27/2026, 11:32 AM investing rating_growth Analysts: analysts, Barclays software

Barclays has upgraded Sandisk's stock rating to overweight and raised its price target significantly, indicating strong potential for further gains amid ongoing demand for memory products.

Analysts Melius Research raised Apple (AAPL) target price to $385, anticipating significant improvements in Siri with Google’s AI partnership

05/26/2026, 09:34 PM economy rating_growth Analysts: analysts, Melius ai software

Apple's upcoming Worldwide Developers Conference (WWDC) on June 8 is critical for the company's stock momentum, as investors are eager to see advancements in its artificial intelligence capabilities, particularly with Siri, following a partnership with Google.

Analysts Bank of America raised Apple (AAPL) target price to $380, citing AI shift as a growth opportunity

05/26/2026, 05:36 PM investing rating_growth Analysts: analysts, Bank of America ai software

Bank of America has upgraded its outlook on Apple, raising its price target to $380, citing the company's potential to leverage artificial intelligence advancements through its user data control.

Analysts UBS raised Micron Technology (MU) target price to $1,625 on strong AI demand for memory chips

05/26/2026, 03:34 PM economy rating_growth Analysts: analysts, UBS ai semiconductors

Micron's stock surged 18%, pushing its market value past $1 trillion for the first time, fueled by strong demand for memory chips driven by artificial intelligence applications. UBS's significant price target increase reflects optimism about Micron's growth potential in the evolving tech landscape.

Analysts Goldman Sachs initiate coverage of Hemab Therapeutics (HEMA) with Buy rating and $36 target price, citing potential for unique bleeding disorder treatment

05/26/2026, 02:32 PM investing rating_growth Analysts: analysts, Goldman Sachs biotech

Hemab Therapeutics is positioned for significant growth following its IPO, driven by its development of unique treatments for rare bleeding disorders, as highlighted by Goldman Sachs' bullish outlook.